Advanced lung cancer inflammation index (ALI) association with increased risk of immune-related adverse events (irAEs) among non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy

V. Bhat; M. Millward; E. S. Gray; A. Abed

doi:10.1016/j.annonc.2022.07.1212

Advanced lung cancer inflammation index (ALI) association with increased risk of immune-related adverse events (irAEs) among non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy

V. Bhat
, M. Millward
, E. S. Gray
, A. Abed

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S1049-S1049
Number of pages	1
Journal	Annals of Oncology
Volume	33
Issue number	7
DOIs	https://doi.org/10.1016/j.annonc.2022.07.1212
Publication status	Published - Sept 2022
Event	2022 Annual Meeting of the European-Society-for-Medical-Oncology - , France Duration: 9 Sept 2022 → 13 Sept 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2022.07.1212

Cite this

@article{7d5f44dcf49e4de597698e4594bbc330,

title = "Advanced lung cancer inflammation index (ALI) association with increased risk of immune-related adverse events (irAEs) among non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy",

author = "V. Bhat and M. Millward and Gray, \{E. S.\} and A. Abed",

year = "2022",

month = sep,

doi = "10.1016/j.annonc.2022.07.1212",

language = "English",

volume = "33",

pages = "S1049--S1049",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

number = "7",

note = "2022 Annual Meeting of the European-Society-for-Medical-Oncology, ESMO 2022 ; Conference date: 09-09-2022 Through 13-09-2022",

}

Advanced lung cancer inflammation index (ALI) association with increased risk of immune-related adverse events (irAEs) among non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy. / Bhat, V.; Millward, M.; Gray, E. S. et al.
In: Annals of Oncology, Vol. 33, No. 7, 09.2022, p. S1049-S1049.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - Advanced lung cancer inflammation index (ALI) association with increased risk of immune-related adverse events (irAEs) among non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy

AU - Bhat, V.

AU - Millward, M.

AU - Gray, E. S.

AU - Abed, A.

PY - 2022/9

Y1 - 2022/9

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000866211601351

U2 - 10.1016/j.annonc.2022.07.1212

DO - 10.1016/j.annonc.2022.07.1212

M3 - Abstract/Meeting Abstract

SN - 0923-7534

VL - 33

SP - S1049-S1049

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

T2 - 2022 Annual Meeting of the European-Society-for-Medical-Oncology

Y2 - 9 September 2022 through 13 September 2022

ER -

Advanced lung cancer inflammation index (ALI) association with increased risk of immune-related adverse events (irAEs) among non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy

UN SDGs

Access to Document

Other files and links

Advanced lung cancer inflammation index (ALI) association with increased risk of immune related adverse events (irAE) among non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy

Cite this